Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07805369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer

Name: A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer — clinical trial record (NCT07805369)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorDEM BioPharma, Inc.

Started2026-09

View on ClinicalTrials.gov ↗

This is a first-in-human Phase 1 study of DEM301 in adults with previously treated advanced metastatic colorectal cancer. DEM301 is an investigational antibody-drug conjugate. The study will evaluate the safety and tolerability of DEM301, identify doses for further study, and assess how the drug behaves in the body and whether it shows signs of activity against the cancer.

Trial Details

NCT Number	NCT07805369
Lead Sponsor	DEM BioPharma, Inc.
Conditions	Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Enrollment	60 participants
Start Date	2026-09
Primary Completion	2028-09 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-04